Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study - Test2 - elhamkhani - TriplyDB

Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study

Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study

http://www.wikidata.org/entity/Q24653006

about

Can tissue-based immune markers be used for studying the natural history of cancer?Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies Advances in understanding monoclonal gammopathy of undetermined significance as a precursor of multiple myeloma Prevention of progression in monoclonal gammopathy of undetermined significance Novel strategies to target the ubiquitin proteasome system in multiple myeloma Cancer stem cells are the cause of drug resistance in multiple myeloma: fact or fiction?Does my patient with a serum monoclonal spike have multiple myeloma?Many multiple myelomas: making more of the molecular mayhem Early lymphoid lesions: conceptual, diagnostic and clinical challenges Multiple myeloma: 2014 Update on diagnosis, risk-stratification, and management Molecular pathogenesis of multiple myeloma: basic and clinical updates Evolving Paradigms in the Management of Multiple Myeloma: Novel Agents and Targeted Therapies Epidemiology of invasive pneumococcal infections: manifestations, incidence and case fatality rate correlated to age, gender and risk factors The insulin-like growth factor system in multiple myeloma: diagnostic and therapeutic potential The Haematological Malignancy Research Network (HMRN): a new information strategy for population based epidemiology and health service research Multiple myeloma epidemiology and survival: A unique malignancy.Development and Validation of an Algorithm to Identify Patients with Multiple Myeloma Using Administrative Claims Data.Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents.Evaluation of the QTc prolongation potential of a monoclonal antibody, siltuximab, in patients with monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, or low-volume multiple myeloma.Predictors of plasma cell disorders among African American patients: a community practice perspective.Eef1a2 promotes cell growth, inhibits apoptosis and activates JAK/STAT and AKT signaling in mouse plasmacytomas.Identification of translocation products but not K-RAS mutations in memory B cells from patients with multiple myeloma.Polycomb target genes are silenced in multiple myeloma.Novel therapies in multiple myeloma for newly diagnosed nontransplant candidates Genetic interrogation of circulating multiple myeloma cells at single-cell resolution.The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network.Circulating serum free light chains as predictive markers of AIDS-related lymphoma.Multiple myeloma in Niger Delta, Nigeria: complications and the outcome of palliative interventions.Osteoblastogenesis and tumor growth in myeloma.Plasma cell neoplasia after kidney transplantation: French cohort series and review of the literature.Applying mass spectrometry based proteomic technology to advance the understanding of multiple myeloma.Racial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12,482 persons from the National Health and Nutritional Examination Survey.Implications of heterogeneity in multiple myeloma.The t(14;20) is a poor prognostic factor in myeloma but is associated with long-term stable disease in monoclonal gammopathies of undetermined significance Transcriptome analysis reveals molecular profiles associated with evolving steps of monoclonal gammopathies.Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study Increased serum free light chains precede the presentation of immunoglobulin light chain amyloidosis.Global gene expression profiling in mouse plasma cell tumor precursor and bystander cells reveals potential intervention targets for plasma cell neoplasia.Obesity is associated with an increased risk of monoclonal gammopathy of undetermined significance among black and white women Medication use and multiple myeloma risk in Los Angeles County.

P2860

Q24605537-FB3337D5-7F7B-4A41-9EB2-9090FE67D218 Q24607241-E576CEC8-1906-472E-A1F0-845F681C5F66 Q24619589-D69AD097-4E59-4C8E-9803-BAAADEFE5019 Q24655581-3D72C9FB-BE85-4EC9-B8EB-92884ECD137B Q26773246-E99852CD-27EA-4B5C-9DD5-785B26B9F216 Q26785497-C2477C61-D62E-44BF-B94A-F40CDCE2B7B9 Q26821981-7D1E2828-1E64-4BBC-98EA-2771C313959A Q26852892-80CDFF77-1E16-4503-AA6B-E977EF51DAA7 Q26996519-AE36EC00-2BAA-4BB5-B58F-BFA8A4B9616F Q26998884-8EE9F48E-289B-4B7F-A030-F6A7538D8787 Q27026205-782456BE-2C67-4172-8DA6-C274D3BE1C72 Q27026478-C0A2C00B-B61E-4377-9BA5-FCFAD1F728BA Q27685556-05E86407-E6E2-46B8-B8C2-6338E2FD6F65 Q28075927-CC937A6F-9197-45D7-8491-8D64DE09E6A1 Q28266484-9201B1FA-2733-478D-9CFA-C513CAF698B7 Q30239771-B439AD85-CEFE-4ED1-BCB8-66EC5FE7722F Q31141905-23142906-EED6-4006-A42B-42E929FB4C95 Q33401759-B1A4B795-D504-4369-9D47-DB3FE5A58040 Q33411075-7BA868B6-4A8E-40A9-9383-61A8B045C500 Q33412193-1158FC20-F1BD-48E1-9135-180F507D061A Q33588550-DAFB0007-A09E-41B8-9709-43B9CFC72F26 Q33590627-46690299-BA60-46A8-80CA-A23E1F2A52FB Q33633898-6427F75A-8D6E-4613-B7A4-8B05F6A35AA1 Q33639796-7943834B-6BD2-4B6D-9311-07A8E04BA421 Q33664484-D4C394B9-31F4-4D0B-A142-536EFAEDE2A9 Q33695919-9F69AB93-8384-4B41-B39A-E269A15A2552 Q33710567-D573A8B8-7914-4A9F-AF78-3280AB3DDD8F Q33734421-BECDC7D0-4E9C-42A8-AFEA-3D9963344B2D Q33768466-86662C33-582E-4550-99FA-E155DCACF07F Q33821866-F49F73CC-51A3-4C30-9A5D-3540E27EBA7D Q33846310-B6628D41-9D65-47E6-BF68-203FFC82BABD Q33875675-EFAAA7D4-CEB4-46D9-A3EB-253F604CEBD3 Q33914824-F43B1C03-FD8A-4B28-99EC-7FB20573D7D5 Q33952861-A7111CE8-7787-4E38-A419-7CCCB733BE45 Q33978937-9518DDF9-32AD-4882-9C3B-925469BDBF89 Q33997173-35361E82-1150-4A2C-AD6F-B655EC71023F Q34091229-5F36006F-3652-475D-98C0-8A737ED51A75 Q34093292-4F5EE7F2-896E-494F-A11C-03FBA6C70EF5 Q34122305-31E117E2-4CCB-4000-BD55-DF2405FECC68 Q34145450-F657546A-360C-4305-B8BD-C68329582B23

P2860

Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study

http://www.wikidata.org/entity/Q24653006

description

2009 nî lūn-bûn

@nan

2009 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Monoclonal gammopathy of undet ...... e myeloma: a prospective study

@ast

Monoclonal gammopathy of undet ...... e myeloma: a prospective study

@en

Monoclonal gammopathy of undet ...... e myeloma: a prospective study

@nl

type

label

Monoclonal gammopathy of undet ...... e myeloma: a prospective study

@ast

Monoclonal gammopathy of undet ...... e myeloma: a prospective study

@en

Monoclonal gammopathy of undet ...... e myeloma: a prospective study

@nl

prefLabel

Monoclonal gammopathy of undet ...... e myeloma: a prospective study

@ast

Monoclonal gammopathy of undet ...... e myeloma: a prospective study

@en

Monoclonal gammopathy of undet ...... e myeloma: a prospective study

@nl

P1433

Q24653006-B570CBE4-9319-45A0-88B9-8EF227975FB2

P1476

Q24653006-7BF1E22C-025B-46DE-8E4D-B83DAD3C9407

P2093

Q24653006-1949ACAD-CBC0-4CD5-BC60-F9E15D05E7A5

Q24653006-48840AB6-6ABB-422D-B7A4-92333D2B7C62

Q24653006-AA9D2BE7-7A66-4CFB-B0D1-F01D8B3E39BB

Q24653006-E9155CC0-7F40-4444-AB4B-E17096447511

Q24653006-F7B8DDE3-6332-47B2-949B-AC702CA2914B

Q24653006-FAF99DFD-B21B-4895-9562-D6C785FB7495

Q24653006-FD9257AE-C12C-4B25-B959-71D6C52A681D

P2860

Q24653006-15D868A7-3117-4FBC-946B-BA074884583F

Q24653006-1D24D128-F301-4DF5-AF1E-C13FCD884A49

Q24653006-1DCE861E-84CB-4E8C-A846-6A6D21DF7CA3

Q24653006-3A87664B-BB9A-4C3C-98F0-65C8FF2D8896

Q24653006-5B759051-ABAF-46B0-9CBC-9440B7C446A3

Q24653006-62FF1801-F7C7-484F-869B-02CEB8205E58

Q24653006-63A21222-1BFD-4BCE-A3C5-EC85A26E89E4

Q24653006-959BCE6B-497C-4571-812B-C4168FECBFF0

Q24653006-95B929CF-C3FF-4D98-9BB5-D36C187D8582

Q24653006-96196F94-6AAD-412F-A7C6-0782A77522FA

P304

Q24653006-33D2D1F0-C6A2-4FFC-833F-D85C9BDEEA04

P31

Q24653006-7A4DEF7F-C7B8-4907-93A3-4CD2E43BB4BE

P3181

Q24653006-4823C7BB-A202-49CA-B2D5-A18E82472B24

P356

Q24653006-05FAE78F-8D44-4BE6-83D4-2EAE3DEF68D0

P407

Q24653006-7F900C81-F5C5-4B5F-8E04-35772C6E4512

P433

Q24653006-FBA13582-B535-4687-A0DA-89195739D501

P478

Q24653006-CF141785-8DDA-435F-A778-5178B6CD820D

P50

Q24653006-62AF728D-3495-45BF-9813-3A207A464291

Q24653006-67F680AE-1EB8-4792-B8A9-A155F83C226B

Q24653006-72908AC3-C152-4F20-8AD7-A996D89B7E44

Q24653006-DE69DA01-E6A0-45AD-A137-BAD0AC947427

Q24653006-EE5E57BE-2FDD-4BD9-B645-6D9DD075BABB

P577

Q24653006-FB4A890F-1D38-49DB-BE0D-61A161C5EC03

P5875

Q24653006-A72E3555-4800-468B-8FFC-D755B990796A

P698

Q24653006-02CEFB41-3CE7-4A3F-ACBB-6E15AC0B156B

P921

Q24653006-D42F61DB-E9CB-4A1D-AD41-10FD6C3B68BC

P932

Q24653006-1F0DD0D1-E566-422E-B609-B6FB3F4BBDEB

P3181

P356

BLOOD-2008-12-194241

P1433

P1476

Monoclonal gammopathy of undet ...... e myeloma: a prospective study

@en

P2093

Dalsu Baris

http://www.w3.org/2001/XMLSchema#string

Jerry A Katzmann

http://www.w3.org/2001/XMLSchema#string

Neil E Caporaso

http://www.w3.org/2001/XMLSchema#string

Raynell J Clark

http://www.w3.org/2001/XMLSchema#string

Robert Hoover

http://www.w3.org/2001/XMLSchema#string

Ruth M Pfeiffer

http://www.w3.org/2001/XMLSchema#string

Shaji Kumar

http://www.w3.org/2001/XMLSchema#string

P2860

Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance

Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group

Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains

Longitudinal data analysis for discrete and continuous outcomes

Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma.

Multiple myeloma.

Prevalence of monoclonal gammopathy of undetermined significance.

Multiple myeloma: evolving genetic events and host interactions.

Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis.

Advances in biology of multiple myeloma: clinical applications.

P304

5412-7

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1783952

http://www.w3.org/2001/XMLSchema#string

P356

10.1182/BLOOD-2008-12-194241

http://www.w3.org/2001/XMLSchema#string

P407

P433

22

http://www.w3.org/2001/XMLSchema#string

P478

113

http://www.w3.org/2001/XMLSchema#string

P50

Richard B Hayes

Angela Dispenzieri

S. Vincent Rajkumar

P577

2009-05-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23959561

http://www.w3.org/2001/XMLSchema#string

P698

19179464

http://www.w3.org/2001/XMLSchema#string

P921

P932

2689042

http://www.w3.org/2001/XMLSchema#string